The Biden administration on Thursday ruled out that it has imposed any kind of restrictions on export of COVID-19 vaccines, amidst reports that European Union has been told by the US that they cannot expect any AstraZeneca shipments anytime soon.
"We don't purchase AstraZeneca supplies. So there's no export prohibitions and all vaccine manufacturers in the United States are free to export their products while also fulfilling the terms of their contracts with the US government," White House Press Secretary Jen Psaki told reporters at her daily news conference.
Vaccine manufacturers in the United States are free to export their products while also fulfilling the terms of contracts with the United States. There are supplies that they are producing for the United States but they can also work with other countries, she said in response to a question.
These companies can work with other countries on selling their products, she said.
"We have conveyed privately what we've conveyed publicly which is our focus is on ensuring the American people are receiving the vaccine and that we are vaccinating the American public," she said.
"That's our first priority. But we are also engaging with and working with the global community to figure out how we can get the global pandemic under control together. Whether that's through financial contributions or through you know, navigating with them how we can work together to address it. But we'll continue to evaluate as more vaccines become available in the United States. AstraZeneca isn't even approved at this point," Psaki said.
She said any company can work with any country around the world on the purchase of vaccine supply. "And certainly, that wouldn't be something the US government would be directly engaged with. But in terms of the supply we have purchased our first focus, our primary focus is on vaccinating the American people. That is what we've conveyed publicly and privately as well," Psaki said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)